Ryaltris Shortage: What Providers and Prescribers Need to Know in 2026

For providers managing patients with seasonal allergic rhinitis, Ryaltris (Olopatadine/Mometasone) has become a valuable tool — a fixed-dose combination nasal spray offering both antihistamine and corticosteroid relief in a single delivery device. But prescribing Ryaltris comes with a familiar challenge: ensuring your patients can actually fill the prescription.

This briefing covers the current availability landscape, prescribing considerations, cost and access barriers, and tools you can use to help your patients get their medication.

Current Shortage Status and Timeline

As of early 2026, Ryaltris is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortage Resource Center. There is no formal nationwide shortage attributed to manufacturing disruptions or raw material constraints.

However, providers should be aware that pharmacy-level stock-outs are common, particularly during peak allergy seasons (March–May and September–November). These are driven by:

• Single-source manufacturing: Ryaltris is manufactured exclusively by Hikma Specialty USA Inc. (licensed from Glenmark Pharmaceuticals). No generic equivalent exists.
• Seasonal demand spikes: Prescribing volume increases sharply during pollen seasons, outpacing pharmacy-level inventory at many retail locations.
• Formulary and inventory biases: Many chain pharmacy inventory systems deprioritize low-volume brand-name products, resulting in inconsistent stocking.

Since Ryaltris received FDA approval in January 2022 and launched commercially in August 2022, there have been no reported prolonged supply disruptions from the manufacturer. Stock-outs have remained localized and intermittent.

Prescribing Implications

Clinical Profile

Ryaltris delivers 665 mcg Olopatadine Hydrochloride and 25 mcg Mometasone Furoate per spray. The recommended dose is 2 sprays per nostril twice daily for patients 12 years and older. Onset of action occurs within approximately 15 minutes, driven primarily by the antihistamine component.

Key clinical considerations:

• Dual mechanism: Olopatadine provides rapid antihistamine relief (H1 receptor antagonism), while Mometasone provides sustained anti-inflammatory action. This combination has demonstrated superiority over either component alone in clinical trials.
• Warnings: Monitor for nasal septal perforation, Candida infection, immunosuppression, adrenal suppression, and growth effects in adolescents. Instruct patients on proper nasal spray technique to minimize epistaxis risk.
• CYP3A4 interactions: Caution with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, itraconazole) due to potential increased systemic exposure to Mometasone. For a detailed breakdown of interactions, see our Ryaltris drug interactions guide.
• Not a controlled substance. No DEA scheduling concerns.

When to Prescribe Ryaltris vs. Alternatives

Ryaltris is most appropriate when:

• Patients report both nasal congestion/inflammation and histamine-driven symptoms (sneezing, itching, rhinorrhea, ocular symptoms)
• Single-agent therapy (corticosteroid alone or antihistamine alone) has been insufficient
• Medication adherence is a concern — a single combination product improves compliance over two separate sprays
• Patients prefer Olopatadine over Azelastine due to better taste tolerability

Consider alternatives when:

• Cost or availability is a barrier — generic Azelastine/Fluticasone (Dymista generic) offers similar dual-action at lower cost
• Formulary restrictions require step therapy through OTC options first
• Symptoms are mild enough to be managed with a single-agent OTC steroid (Fluticasone, Mometasone) or antihistamine

Availability Picture

The pharmacy-level availability of Ryaltris varies significantly by region and pharmacy type:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Stock may be inconsistent. Automated inventory systems may not reorder Ryaltris proactively if dispensing volume is low at a given location.
• Independent pharmacies: Often more responsive to special orders and may stock Ryaltris if they have regular patients using it.
• Mail-order pharmacies: Generally reliable for Ryaltris supply, and may offer better pricing through insurance-negotiated rates.
• Specialty pharmacies: Allergy-focused practices with dispensing capabilities may maintain dedicated stock.

Providers can direct patients to Medfinder for Providers to check real-time pharmacy availability in their area.

Cost and Access Landscape

Understanding the cost barriers your patients face is critical to successful prescribing:

• Average cash price: $235–$333 per bottle (29g, ~240 sprays)
• Ryaltris Savings Card: Commercially insured patients may pay as little as $39/bottle; cash-paying patients may pay as little as $45.52/bottle. Maximum benefit of $200 per bottle. Available via GoodRx/Hikma partnership at us.ryaltris.com/savings-and-support.
• Discount card pricing: GoodRx, SingleCare, and other platforms offer coupons bringing the price to approximately $245–$280.
• Insurance: Coverage varies. Many commercial plans cover Ryaltris but may require prior authorization or step therapy. Medicare Part D coverage varies by plan.

For patients who cannot afford Ryaltris even with savings programs, Hikma offers patient assistance. Contact 1-800-631-2174 or visit us.ryaltris.com/savings-and-support. Additional resources are available through NeedyMeds and RxAssist.

For a patient-facing savings resource you can share, see how to save money on Ryaltris.

Tools and Resources for Providers

Several tools can streamline the process of getting Ryaltris into your patients' hands:

• Medfinder for Providers: Check real-time pharmacy availability for Ryaltris and other medications. Help patients identify which nearby pharmacies have stock before they leave your office.
• Prior authorization support: When submitting PAs, document prior trials of OTC corticosteroids and antihistamines, symptom severity, and the clinical rationale for combination therapy.
• Samples: Healthcare providers may request Ryaltris samples by filling out a form on the Hikma provider portal.
• E-prescribing to preferred pharmacies: If you know a patient's preferred pharmacy stocks Ryaltris, e-prescribe directly there. For patients who have difficulty finding it, consider prescribing to a mail-order pharmacy.

Alternative Prescribing Strategies

When Ryaltris is unavailable or unaffordable, consider these evidence-based alternatives:

1. Generic Azelastine/Fluticasone (Dymista generic): Most direct substitute. Available from multiple generic manufacturers. Cost: $30–$80 with coupons.
2. Step-down approach: OTC Fluticasone (Flonase) or generic Mometasone + OTC Azelastine (Astepro). Two separate sprays but significantly lower cost ($20–$40 total).
3. Single-agent steroid: Generic Mometasone or OTC Fluticasone for patients whose primary symptom is congestion.
4. Single-agent antihistamine: OTC Astepro (Azelastine) for patients whose primary symptoms are sneezing, itching, and rhinorrhea.

For a patient-facing guide on alternatives, share alternatives to Ryaltris.

Looking Ahead

No generic equivalent for Ryaltris has been announced as of early 2026. Given the patent landscape for combination nasal spray products, generic entry may still be several years away. Providers should anticipate continued brand-name pricing and potential pharmacy-level stock variability for the foreseeable future.

Key trends to watch:

• Potential expansion of the OTC allergy nasal spray market, which may increase patient options for step therapy
• Telehealth-driven prescribing growth, which may shift more Ryaltris dispensing to mail-order pharmacies with more reliable stock
• Possible Hikma pricing or access program expansions in response to competitive pressure from generic Dymista

Final Thoughts

Ryaltris remains a clinically valuable option for seasonal allergic rhinitis, offering the convenience of dual-action therapy in a single nasal spray device. While no formal shortage exists, providers should be proactive about managing patient expectations around availability and cost.

Equipping your practice with tools like Medfinder for Providers, directing patients to manufacturer savings programs, and having alternative prescribing strategies ready will help ensure your patients get effective allergy relief — even when first-choice therapy faces access challenges.

For a companion patient guide, see Ryaltris shortage update: what patients need to know in 2026. For help with patient cost concerns, see our provider's guide to helping patients save money on Ryaltris.